母細胞性漿細胞樣樹突狀細胞腫瘤（BPDCN）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 法國市場預計將從約 830 萬美元成長到約 1,740 萬美元（年複合成長率約 7-8%）。
• 雖然患者人數不多，但由於標靶治療和診斷技術的進步，預計患者人數將會成長。

漿細胞樣樹突狀細胞腫瘤（BPDCN）概述

漿細胞樣樹突狀細胞腫瘤（BPDCN）是一種罕見的、侵襲性強的骨髓惡性腫瘤，預後不良，起源於漿細胞樣樹突狀細胞前驅細胞。最常見的症狀是皮膚浸潤，患者通常表現為無症狀的皮損，從胎記到斑塊和結節不等，常涉及大面積皮膚。

除了皮膚外，BPDCN 也常擴散至骨髓、淋巴結、脾臟和中樞神經系統 (CNS)，引起包括血球減少和器官浸潤在內的全身性病變。此病屬於樹突狀細胞和組織細胞腫瘤，常與其他血液系統惡性腫瘤相關或進展為其他骨髓惡性腫瘤。

此疾病主要影響老年人，男性患者較多（男女比例約3:1至5:1）。通常在60至70歲之間確診。儘管治療方法有所進步，但由於其侵襲性強、復發率高且長期治療選擇有限，BPDCN仍然是一種臨床上具有挑戰性的疾病。

主要亮點

• BPDCN 是一種罕見且侵襲性強的骨髓惡性腫瘤，存在著巨大的未滿足醫療需求。
• 預計美國病例數將從約 1800 例增加到約 2400 例（年複合成長率約 3%）。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Chongqing Precision Biotech Co. Ltd
• AbbVie
• Stemline Therapeutics

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
• 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Outlook

Thelansis's "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Blastic Plasmacytoid Dendritic Cell Neoplasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with a poor prognosis, arising from precursors of plasmacytoid dendritic cells. It most commonly presents with cutaneous involvement, where patients develop asymptomatic lesions ranging from bruise-like patches to plaques or nodules, often involving large body areas.

Beyond the skin, BPDCN frequently involves the bone marrow, lymph nodes, spleen, and central nervous system (CNS), leading to systemic disease manifestations including cytopenias and organ infiltration. It is classified under dendritic cell and histiocytic neoplasms and is often associated with or evolves into other hematologic malignancies.

The disease predominantly affects older adults, with a strong male predominance (male-to-female ratio ~3:1 to 5:1), and is typically diagnosed between 60-70 years of age. Despite advances, BPDCN remains clinically challenging due to its aggressive nature, high relapse rates, and limited long-term treatment options.

Key Highlights

• BPDCN is a rare, aggressive hematologic malignancy with high unmet need
• US incidence expected to increase from ~1.8K to ~2.4K (~3% CAGR)

Market Overview

• France market projected to grow from ~$8.3M to ~$17.4M (~7-8% CAGR)
• Growth driven by targeted therapies and improved diagnosis, despite small patient population

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Chongqing Precision Biotech Co. Ltd
• AbbVie
• Stemline Therapeutics

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)